Precigen, Inc. (PGEN)
6.19
-0.20
(-3.13%)
USD |
NASDAQ |
Oct 23, 16:00
6.185
0.00 (0.00%)
After-Hours: 20:00
Precigen Enterprise Value : 2.276B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 2.276B |
| October 22, 2026 | 2.348B |
| October 21, 2026 | 2.423B |
| October 20, 2026 | 2.505B |
| October 19, 2026 | 2.444B |
| October 16, 2026 | 2.346B |
| October 15, 2026 | 2.636B |
| October 14, 2026 | 2.693B |
| October 13, 2026 | 2.738B |
| October 12, 2026 | 2.802B |
| October 09, 2026 | 2.856B |
| October 08, 2026 | 2.781B |
| October 07, 2026 | 2.760B |
| October 06, 2026 | 2.763B |
| October 05, 2026 | 2.831B |
| October 02, 2026 | 3.118B |
| October 01, 2026 | 2.999B |
| September 30, 2026 | 3.125B |
| September 29, 2026 | 2.942B |
| September 28, 2026 | 2.856B |
| September 25, 2026 | 2.835B |
| September 24, 2026 | 2.817B |
| September 23, 2026 | 2.724B |
| September 22, 2026 | 2.885B |
| September 21, 2026 | 2.817B |
| Date | Value |
|---|---|
| September 18, 2026 | 2.845B |
| September 17, 2026 | 2.878B |
| September 16, 2026 | 2.722B |
| September 15, 2026 | 2.566B |
| September 14, 2026 | 2.512B |
| September 11, 2026 | 2.512B |
| September 10, 2026 | 2.452B |
| September 09, 2026 | 2.495B |
| September 08, 2026 | 2.520B |
| September 04, 2026 | 2.602B |
| September 03, 2026 | 2.616B |
| September 02, 2026 | 2.570B |
| September 01, 2026 | 2.516B |
| August 31, 2026 | 2.541B |
| August 28, 2026 | 2.548B |
| August 27, 2026 | 2.634B |
| August 26, 2026 | 2.717B |
| August 25, 2026 | 2.666B |
| August 24, 2026 | 2.627B |
| August 21, 2026 | 2.638B |
| August 20, 2026 | 2.724B |
| August 19, 2026 | 2.623B |
| August 18, 2026 | 2.477B |
| August 17, 2026 | 2.405B |
| August 14, 2026 | 2.244B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 273.50M |
| Aldeyra Therapeutics, Inc. | -5.756M |
| Repligen Corp. | 9.864B |
| AC Immune SA | 132.13M |
| Amgen, Inc. | 280.78B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.07M |
| Revenue (Quarterly) | 54.98M |
| Total Expenses (Quarterly) | 34.91M |
| EPS Diluted (Quarterly) | 0.0485 |
| Gross Profit Margin (Quarterly) | 94.32% |
| Profit Margin (Quarterly) | 36.51% |
| Earnings Yield | -17.76% |
| Normalized Earnings Yield | -13.66 |